Jerry Radich

903 total citations
29 papers, 602 citations indexed

About

Jerry Radich is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Jerry Radich has authored 29 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 17 papers in Genetics and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Jerry Radich's work include Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Acute Lymphoblastic Leukemia research (10 papers). Jerry Radich is often cited by papers focused on Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Acute Lymphoblastic Leukemia research (10 papers). Jerry Radich collaborates with scholars based in United States, Germany and United Kingdom. Jerry Radich's co-authors include Claudio Anasetti, Rainer Storb, Paul J. Martin, Frederick R. Appelbaum, Richard A. Nash, CD Buckner, John A. Hansen, R Clift, FR Appelbaum and Brenda M. Sandmaier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jerry Radich

27 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerry Radich United States 11 518 248 168 111 89 29 602
Hans-Jochen Kölb Germany 8 548 1.1× 294 1.2× 74 0.4× 106 1.0× 99 1.1× 11 666
C. Fabères France 15 625 1.2× 296 1.2× 128 0.8× 170 1.5× 95 1.1× 30 709
Hagop M. Kantarjian United States 11 437 0.8× 256 1.0× 318 1.9× 78 0.7× 81 0.9× 17 650
M Shtalrid Israel 12 309 0.6× 213 0.9× 78 0.5× 81 0.7× 68 0.8× 28 461
G Meloni Italy 11 461 0.9× 268 1.1× 99 0.6× 118 1.1× 81 0.9× 24 547
SL George United States 9 457 0.9× 169 0.7× 264 1.6× 62 0.6× 169 1.9× 14 597
Berit Markevärn Sweden 16 671 1.3× 558 2.3× 112 0.7× 204 1.8× 199 2.2× 30 796
Milena Fava Italy 8 764 1.5× 352 1.4× 296 1.8× 203 1.8× 389 4.4× 10 949
RS Negrin United States 10 515 1.0× 123 0.5× 143 0.9× 31 0.3× 126 1.4× 13 624
Tsuyoshi Takahashi Japan 9 408 0.8× 119 0.5× 75 0.4× 35 0.3× 91 1.0× 22 529

Countries citing papers authored by Jerry Radich

Since Specialization
Citations

This map shows the geographic impact of Jerry Radich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Radich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Radich more than expected).

Fields of papers citing papers by Jerry Radich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Radich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Radich. The network helps show where Jerry Radich may publish in the future.

Co-authorship network of co-authors of Jerry Radich

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Radich. A scholar is included among the top collaborators of Jerry Radich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Radich. Jerry Radich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Radich, Jerry. (2022). Introduction to the Series on Measurable Residual Disease. Haematologica. 107(12). 2782–2782.
2.
Yeung, Cecilia C.S., et al.. (2021). Mutational profiling in acute lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing. Cancer Medicine. 10(16). 5629–5642. 4 indexed citations
3.
Branford, Susan, Dennis Dong Hwan Kim, Jane F. Apperley, et al.. (2019). Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 33(8). 1835–1850. 84 indexed citations
4.
5.
Qu, Xiaoyu, Megan Othus, Jerry Davison, et al.. (2017). Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer. 123(13). 2472–2481. 11 indexed citations
6.
White, Helen, John Hedges, Israel Bendit, et al.. (2013). Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry. 59(6). 938–948. 33 indexed citations
7.
Eissa, Hesham, Ted Gooley, Mohamed L. Sorror, et al.. (2010). Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities. Biology of Blood and Marrow Transplantation. 17(6). 908–915. 81 indexed citations
8.
Hughes, Timothy P., Giovanni Martinelli, Susan Branford, et al.. (2010). Early molecular response to nilotinib in patients who failed imatinib is associated with a higher probability of cytogenetic response in chronic myeloid leukemia (CML). Haematologica. 95. 54–54. 1 indexed citations
9.
Ausch, Christoph, Young Ho Kim, Karen D. Tsuchiya, et al.. (2009). Comparative Analysis of PCR-Based Biomarker Assay Methods for Colorectal Polyp Detection from Fecal DNA. Clinical Chemistry. 55(8). 1559–1563. 45 indexed citations
10.
Saglio, Giuseppe, Jerry Radich, Giovanni Martinelli, et al.. (2008). Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060. Journal of Clinical Oncology. 26(15_suppl). 7060–7060. 5 indexed citations
11.
Sorror, Mohamed L., Barry E. Storer, Brenda M. Sandmaier, et al.. (2007). Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood. 110(11). 1662–1662. 2 indexed citations
12.
Goldman, John M., Timothy P. Hughes, Jerry Radich, et al.. (2005). Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.. Blood. 106(11). 163–163. 20 indexed citations
13.
Jurado, Manuel, H. Joachim Deeg, Barry E. Storer, et al.. (2002). Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biology of Blood and Marrow Transplantation. 8(3). 161–169. 47 indexed citations
14.
Sandmaier, Brenda M., David G. Maloney, Peter A. McSweeney, et al.. (2001). Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences. 938(1). 328–339. 59 indexed citations
15.
Radich, Jerry & Blythe Thomson. (1997). Advances in the detection of minimal residual disease. Current Opinion in Hematology. 4(4). 242–247. 7 indexed citations
16.
Sierra, Jorge, Jerry Radich, John A. Hansen, et al.. (1997). Marrow Transplants From Unrelated Donors for Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood. 90(4). 1410–1414. 6 indexed citations
17.
Radich, Jerry. (1995). Minimal residual disease. Current Opinion in Hematology. 2(4). 300–304. 4 indexed citations
18.
Appelbaum, FR, R Clift, Jerry Radich, Claudio Anasetti, & CD Buckner. (1995). Bone marrow transplantation for chronic myelogenous leukemia.. PubMed. 22(4). 405–11. 56 indexed citations
19.
Clift, R, CD Buckner, Claudio Anasetti, et al.. (1994). Allogeneic marrow transplantation for chronic myeloid leukemia. Medical Oncology. 11(2). 69–74. 9 indexed citations
20.
Collins, SJ, et al.. (1989). Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood. 73(4). 1028–1032. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans-Jochen Kölb Breakdown of academic impact, for papers by C. Fabères Breakdown of academic impact, for papers by Hagop M. Kantarjian Breakdown of academic impact, for papers by M Shtalrid Breakdown of academic impact, for papers by G Meloni Breakdown of academic impact, for papers by SL George Breakdown of academic impact, for papers by Berit Markevärn Breakdown of academic impact, for papers by Milena Fava Breakdown of academic impact, for papers by RS Negrin Breakdown of academic impact, for papers by Tsuyoshi Takahashi
Rankless by CCL
2026